ReviewCurrent infectious disease reports2019
Antifungal Resistance: a Concerning Trend for the Present and Future.
Review in Current infectious disease reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 1 synthesis or guideline pooled it, 138 citations in OpenAlex.
- Optimizing antifungal therapy: a systematic review of pharmacist interventions, stewardship approaches, and outcomes.Frontiers in medicine · 2024Pooled it
- Bioactive Constituents ofACS omega · 2026Article
- Spasmolytic Activity of Plant-Mediated Silver Nanoparticles from Fenugreek Seeds: Impact of Geographic Origin and Extraction Solvent.Nanomaterials (Basel, Switzerland) · 2026Article
- Prevalence, Etiology, and Antifungal Resistance Profiles of Ocular Fungal Infections in Ghanaian Ophthalmic Patients: A Multicenter Cross-Sectional Study.Health science reports · 2026Article
- Biogenic Synthesis, Structural Characterization, and Biological Evaluation of Nanoparticles Derived fromNanomaterials (Basel, Switzerland) · 2026Article
- Synergistic antifungal activity of antiretrovirals with amphotericin B against Aspergillus species.PloS one · 2026Article
- Leveraging Vulnerabilities in Copper Trafficking for Synergistic Antifungal Activity.ACS chemical biology · 2025Article
- Mechanism of azole resistance inJournal of medical microbiology · 2025Article
- Investigation of fungal nosocomial infections and antimicrobial drug resistance pattern after open-heart surgery; a cross-sectional study.Annals of medicine and surgery (2012) · 2025Article
- Fast detection of synergy and antagonism in antifungal combinations used against Candida albicans clinical isolates.Scientific reports · 2025Article
- Novel Synthesis of the Antifungal Cyclic Lipopeptide Iturin A and Its Fluorinated Analog for Structure-Activity Relationship Studies.Chemistry (Weinheim an der Bergstrasse, Germany) · 2025Article
- Expansion of the antibacterial spectrum of symmetrical amino acid-paired antifungal peptides through structural optimization.BMC microbiology · 2025Article
- New Generation Modified Azole Antifungals against Multidrug-ResistantJournal of medicinal chemistry · 2025Article
- Structural Insights into Selectively TargetingBiochemistry · 2025Article
- Functionalized Silver Nanoparticles as Multifunctional Agents Against Gut Microbiota Imbalance and Inflammation.Nanomaterials (Basel, Switzerland) · 2025Article
- Fungi as an emerging waterborne health concern: impact of treated wastewater dischargeEnvironmental science. Processes & impacts · 2025Article
- Synthesis and Antifungal Activity of Fmoc-Protected 1,2,4-Triazolyl-α-Amino Acids and Their Dipeptides AgainstBiomolecules · 2025Article
- Antimicrobial Multidrug Resistance and Mechanisms of Action: An Overview.BioMed research international · 2025Review
- Progress on the Global Research Agenda for Antimicrobial Resistance in Human Health in Pakistan: Findings and Implications.Infection and drug resistance · 2025Review
- Antifungal potential, mechanism of action, and toxicity of 1,4-naphthoquinone derivatives.European journal of microbiology & immunology · 2024Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThe global emergence of antifungal resistance among Candida spp. and Aspergillus spp. is a growing threat to public health, driven largely by the expanding use of antifungals in both the clinical and agricultural settings. As treatment options remain limited, understanding mechanisms and risk factors for antifungal resistance is essential to retaining their clinical utility. RECENT
findingsInvasive candidiasis is increasingly caused by non-albicans Candida species with reduced susceptibility to first-line antifungals, making empiric treatment decisions difficult. Echinocandin resistance in C. glabrata is increasing at some high-risk centers, and multi-drug-resistant isolates are increasingly encountered. Of large concern is the rapid and global emergence of C. auris, a species associated with a high propensity for developing multi-drug resistance and nosocomial transmission. Azole resistance is now becoming more common in Aspergillus isolates as well, with breakthrough infections occurring in patients previously managed with azoles antifungals. The appearance of azole-resistant Aspergillus isolates in azole-naïve patients is also concerning, given it is now accepted that this may be due to the use of non-human azole compounds in pesticides. Due to the climbing use of antifungals in both the clinical and agricultural sectors, the frequency of encounters with antifungal-resistant isolates will undoubtedly rise in parallel. Antifungal stewardship will need to become a new priority for antimicrobial stewardship programs in order to preserve our current selection of antifungal agents. Rapid diagnostics may help stewardship efforts by decreasing the time it takes to determine if an antifungal agent is indicated for a patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.